- Abstract Number: 1834 • 2015 ACR/ARHP Annual Meeting - Total Hip Arthroplasty Outcomes: A 17 Year Experience in a Single-Center: Is Systemic Lupus Erythematosus a Real Risk Factor for Adverse Outcomes?Background/Purpose: In patients with systemic lupus erythematosus (SLE), persistent joint activity and treatment with glucocorticoids are associated with musculoskeletal complications, including hip osteonecrosis. About 30%…
- Abstract Number: 1835 • 2015 ACR/ARHP Annual Meeting - Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee ReplacementBackground/Purpose: More Systemic Lupus Erythematosus (SLE) patients are undergoing total knee arthroplasty (TKA) with equivalent benefits to osteoarthritis (OA) patients. While post-surgical adverse events (AEs)…
- Abstract Number: 1836 • 2015 ACR/ARHP Annual Meeting - Standardized Incidence Ratio (SIR), Time Trend and Risk Factors of Avascular Bone Necrosis (AVN) in Patients with Systemic Lupus Erythematosus (SLE)Background/Purpose: To study the standardized incidence ratio (SIR), time trend and risk factors of AVN in patients with SLE. Methods: The records of all patients…
- Abstract Number: 1837 • 2015 ACR/ARHP Annual Meeting - Predictability of Musculoskeletal Flares and Hand Deformities in Systemic Lupus Erythematosus By High Resolution Ultrasound : 5-Year Clinical and Imaging Prospective Follow-up StudyBackground/Purpose: SLE patients develop non-deforming non-erosive (NDNE) arthritis in 70-80%, but 5-15% of cases progresses into Jaccoud's arthropathy (JA) a non-erosive deforming arthritis. This study…
- Abstract Number: 1838 • 2015 ACR/ARHP Annual Meeting - Joint Ultrasonography May be Useful to Assess Disease Activity in Systemic Lupus Erythematosus (SLE) Patients: A Prospective Multicenter StudyBackground/Purpose: Arthritis is a current manifestation of SLE and participates to the SLEDAI composite score calculation (0 to 105). Ultrasonography (US) is a validated and…
- Abstract Number: 1839 • 2015 ACR/ARHP Annual Meeting - Safety and Immunogenicity of Quadrivalent Human Papilloma Virus (qHPV) Vaccine (Gardasil®) in Systemic Lupus Erythematous (SLE), Phase I Trial CompletionBackground/Purpose: Women with SLE are at increased risk for HPV-related cervical disease. The qHPV vaccine immunizes and is protective against HPV types that cause the…
- Abstract Number: 1840 • 2015 ACR/ARHP Annual Meeting - How Good a Job Are We Rheumatologists Doing in Screening for Hepatitis B and C before Immuno-Suppressive/s Initiation in SLE?Background/Purpose: Hepatitis B & C viral infections are widely prevalent and the potential of immunosuppressive medications (ISM) to exacerbate an underlying viral infection is well…
- Abstract Number: 1841 • 2015 ACR/ARHP Annual Meeting - Meningitis in Systemic Lupus Erythematosus Patients: Epidemiologic Profile of Listeria Monocytogenes Infection. a Single-Center StudyBackground/Purpose: Infections are an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients. These patients are more prone to develop infections, both…
- Abstract Number: 1842 • 2015 ACR/ARHP Annual Meeting - Systemic Lupus Erythematosus and Chikungunya Fever: Interactions during the 2014 Outbreak in MartiniqueBackground/Purpose: There is no data in the literature about chikungunya fever (chik) and SLE. Martinique (French West Indies) experienced for the first time an outbreak…
- Abstract Number: 1843 • 2015 ACR/ARHP Annual Meeting - Bloodstream Infections in Systemic Lupus Erythematosus Patients Are Associated with Severe Lupus FlaresBackground/Purpose: Infections are an important cause of mortality and morbidity in systemic lupus erythematosus (SLE) patients. Bloodstream infections (BI), which are especially severe and relatively…
- Abstract Number: 1844 • 2015 ACR/ARHP Annual Meeting - Risk Factors for Complicated Pneumonia in Systemic Lupus Erythematosus (SLE)Background/Purpose: Pneumonia, remains as a main cause of mortality in patients with SLE. In patients without autoimmune disease, scores as Pneumonia Severity Index (PSI) and…
- Abstract Number: 1845 • 2015 ACR/ARHP Annual Meeting - HMGB1 Early Marker in Lupus NephritisBackground/Purpose: Systemic Lupus Erythematosis is a systemic autoimmune disease characterised by involvement of multiple organ systems Lupus nephritis (LN) is a severe and frequent manifestation…
- Abstract Number: 1846 • 2015 ACR/ARHP Annual Meeting - IGFBP-2 As a Novel Biomarker for Disease Activity and Renal Pathology in Lupus NephritisBackground/Purpose: Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus. Invasive renal biopsy remains the golden standard for the diagnosis…
- Abstract Number: 1847 • 2015 ACR/ARHP Annual Meeting - Serum Ferritin and Insulin-like Growth Factor-Binding Protein 2 As Biomarkers of Clinical and Histopathological Treatment Response in Lupus NephritisBackground/Purpose: Lupus nephritis (LN) is a severe manifestation of Systemic Lupus Erythematosus (SLE). Renal biopsy is gold standard for evaluation of renal activity and damage…
- Abstract Number: 1848 • 2015 ACR/ARHP Annual Meeting - Increased Expression of Bruton Tyrosine Kinase in Patients with Lupus Nephritis and Its Clinic SignificanceBackground/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease manifested by multiorgan impairment including glomerulonephritis, cutaneous lesions and arthritis. B cells participate in the onset…
